<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150878</url>
  </required_header>
  <id_info>
    <org_study_id>9005-2003</org_study_id>
    <nct_id>NCT00150878</nct_id>
  </id_info>
  <brief_title>Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission</brief_title>
  <official_title>Randomized Phase III Comparison of 12 Gy TBI and Cyclophosphamide 120 mg/kg With Fludarabine 120 mg/Sqm and 8 Gy TBI Before Allogeneic Transplantation in Patients With Acute Myeloid Leukemia in First Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to show that the treatment-related mortality of allogeneic
      hematopoietic stem cell transplantation an be significantly reduced by using a combination of
      8 Gy total-body-irradiation and fludarabine in comparison to the conventional combination of
      12 Gy TBI and 120 mg/kg Cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplant-related deaths because of extramedullary toxicity and graft-versus host disease
      remain the major causes for treatment-failure in patients with AMl receiving allogeneic
      hematopoietic stem cell transplantation.

      In phase II study, M . Stelljes and coworkers could show, that a reduced dose of total-body-
      irradiation and fludarabine can be safely used in patients with AML at various disease
      stages. The best results could be achieved in patients who had been in complete remission by
      the time of inclusion.

      Therefore this prospective trial was initiated to compare the new conditioning regimen with
      the standard regimen of 12 Gy TBI/Cyclophosphamide 120 mg/kg in patients ith AML in first
      remission.

      After having achieved complete remission, and giving informed consent, patients are
      stratified according to marrow cytogenetics, age and type of induction therapy and
      subsequently randomized to receive on of the mentioned conditioning therapies.

      The primary end-point will be non-relapse mortality. The hypothesis would be, that the
      one-year mortality can be reduced from 25 to 15%. Given a power of 0.8 and a first-error of
      5%, 252 patients will have to be randomized.

      Secondary endpoints include:

      3 year overall-and disease-free survival Rate of grade II-IV acute GvHD Rate of grade 3-4
      extramedullary toxicity
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insurance coverage reached
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality at 12 months after transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients dying without prior relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free and Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of patients alive without relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 extramedullary toxicity</measure>
    <time_frame>100 days</time_frame>
    <description>Percentage of patients with grade II-IV acute GvHD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>12 Gy/Cyclophosphamide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard intensity conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Gy /Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced-intensity conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conditioning therapy</intervention_name>
    <description>Preparation before allogeneic transplantation</description>
    <arm_group_label>12 Gy/Cyclophosphamide</arm_group_label>
    <arm_group_label>8 Gy /Fludarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia in first remission

          -  Standard-or high-risk marrow cytogenetics

          -  HLA-matched related or unrelated donor available (in case of high-risk disease)

          -  Age 18 to 60

          -  Informed consent

          -  Consent of donor to donate peripheral blood stem cells

          -  sufficient liver function (elevation of transferases &lt; 2.5 x upper limit)

        Exclusion Criteria:

          -  AML with t(5;17)

          -  AML with t((8;21)

          -  clinically relevant heart failure (NYHA II-IV)

          -  Renal failure (creatinine &gt; 200 Âµg/ml)

          -  Liver function failure (bilirubin &gt; 3 mg/dl)

          -  Concomitant Neurological or psychiatric disease

          -  Contraindications to receive prescribed study medication

          -  HIV infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Ehninger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Med. Klink und Poliklinik I, Technical University Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-leukaemie.de/</url>
    <description>Central Leukemia Study Group</description>
  </link>
  <reference>
    <citation>Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J; Cooperative German Transplant Study Group. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005 Nov 1;106(9):3314-21. Epub 2005 Jul 14.</citation>
    <PMID>16020510</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <name_title>University Hospital Dresden</name_title>
  </responsible_party>
  <keyword>Reduced-intensity conditioning</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Acute myeloid Leukemia</keyword>
  <keyword>Treatment-related mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

